Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Vaccinations
Recent news which mentions Vaccinations
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why a Covid-19 vaccine could soon cost as much as $150—even if you're insured
June 11, 2025
Tags
COVID/19
Make It
Vaccinations
From
CNBC.com News
Trump plans executive orders on military related to DEI, transgender troops and vaccines
January 27, 2025
Tags
Politics
Vaccinations
Armed forces
From
CNBC.com News
Covid-19, flu, RSV: Vaccine recommendations for fall—and the best time to get them
September 06, 2024
Tags
Health Tips and Wellness Advice
Flu
COVID/19
From
CNBC.com News
CNBC Daily Open: Stocks slide ahead of Powell speech
August 22, 2024
Tags
Autos
Deutsche Bank AG
Prices
From
CNBC.com News
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
June 28, 2024
Tags
Pharmaceuticals
Bristol/Myers Squibb Co
Moderna Inc
From
CNBC.com News
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
June 07, 2024
Tags
Health care industry
Companies
Moderna Inc
From
CNBC.com News
CNBC Daily Open: Roaring Kitty's wealth, Modi's victory
June 04, 2024
Tags
Asia Markets
Immunizations
Asia Politics
From
CNBC.com News
CNBC Daily Open: GameStop can't stop, Dow drops
June 04, 2024
Tags
AI / Artificial Intelligence
World Markets
GameStop Corp
From
CNBC.com News
Nobel Prize winner Katalin Karikó was 'demoted 4 times' at her old job. How she persisted: 'You have to focus on what's next'
October 06, 2023
Tags
Vaccinations
Science
Nobel Prizes
From
CNBC.com News
Covid-19, flu, RSV: Here are the vaccine recommendations for fall—and the best time to get them
September 12, 2023
Tags
Health Tips and Wellness Advice
Health
Make It
From
CNBC.com News
Moderna says updated Covid vaccine was effective against highly mutated BA.2.86 variant in trial
September 06, 2023
Tags
Companies
Moderna Inc
Health care industry
From
CNBC.com News
New Covid vaccines from Pfizer, Moderna and Novavax will likely protect against Eris variant
August 18, 2023
Tags
Biotechnology
US: News
Coronavirus
From
CNBC.com News
GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine
August 02, 2023
Tags
Walgreens Boots Alliance Inc
Business News
Pharmaceuticals
From
CNBC.com News
New Covid vaccines are coming to the U.S. this fall, but uptake may be low — Here’s why
July 29, 2023
Tags
Pfizer Inc
Business
Novavax Inc
From
CNBC.com News
GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
July 26, 2023
Tags
Biotechnology
US: News
Health & Science
From
CNBC.com News
Pfizer Group B strep vaccine for infants returns encouraging mid-stage trial results
July 19, 2023
Tags
Health care industry
Companies
Pharmaceuticals
From
CNBC.com News
Biden administration asks Pfizer, Moderna and Novavax for 'reasonable' prices on updated Covid vaccines
July 13, 2023
Tags
Health & Science
Biotechnology
US: News
From
CNBC.com News
Novavax stock spikes 20% after company snags $350 million from Canada for unused Covid shots
July 10, 2023
Tags
Biotech and Pharmaceuticals
Pfizer Inc
Business
From
CNBC.com News
Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says
June 22, 2023
Tags
Biotech and Pharmaceuticals
GSK plc
Vaccinations
From
CNBC.com News
CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults over 60
June 21, 2023
Tags
GSK plc
Vaccinations
Pfizer Inc
From
CNBC.com News
GSK says RSV vaccine for older adults provides protection over two seasons
June 21, 2023
Tags
GSK plc
Vaccinations
Pfizer Inc
From
CNBC.com News
FDA advisors recommend that new Covid vaccines target an omicron XBB variant this fall
June 15, 2023
Tags
Biotech and Pharmaceuticals
Breaking news
Pfizer Inc
From
CNBC.com News
Covid vaccine maker Novavax sees a pathway to survival – but it won’t be easy
June 14, 2023
Tags
Biotech and Pharmaceuticals
Novavax Inc
Vaccinations
From
CNBC.com News
FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns
May 18, 2023
Tags
Vaccinations
GSK plc
Business
From
CNBC.com News
Pfizer RSV vaccine for infants has 'generally favorable' safety data, FDA staff say
May 16, 2023
Tags
GSK plc
Vaccinations
Pfizer Inc
From
CNBC.com News
WHO says mpox outbreak, the largest in history, no longer global health emergency
May 11, 2023
Tags
Vaccinations
Disease outbreaks
Epidemics
From
CNBC.com News
Moderna posts surprise quarterly profit despite waning demand for Covid vaccines
May 04, 2023
Tags
Earnings
Breaking news
Merck & Co Inc
From
CNBC.com News
FDA approves GSK's RSV vaccine for older adults, world's first shot against virus
May 03, 2023
Tags
Breaking news
Breaking News: Business
Biotech and Pharmaceuticals
From
CNBC.com News
Pfizer earnings and revenue top expectations despite sales declines
May 02, 2023
Tags
Earnings
Breaking news
Breaking News: Business
From
CNBC.com News
FDA says Guillain-Barre syndrome is possible risk of Pfizer's RSV vaccine for older adults
February 24, 2023
Tags
U/S/ Economy
Biotech and Pharmaceuticals
Breaking News: Business
From
CNBC.com News
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.